首页 产品中心
  • ICG-001

    • ICG001;ICG 001
    货号: abs810420
    CAS号: 780757-88-2;847591-62-2
    分子式: C33H32N4O4
    分子量: 548.63
    产品说明书
    分享:
    货号-规格 货期 价格 数量
    abs810420-5mg 1-2周 ¥857.00
    - +
    abs810420-10mg 现货 ¥1541.00
    - +
    abs810420-50mg 现货 ¥4744.00
    - +
    abs810420-100mg 现货 ¥7610.00
    - +
    大包装询价
    产品描述
    描述

    ICG-001 is a small-molecule antagonist of b-catenin/TCF-mediated transcription (IC50 = 3 uM) and specifically downregulates the expression of a subset of b-catenin/TCF-responsive genes. ICG-001 binds specifically to cyclic AMP response element-binding pro

    纯度
    >98%
    储存/保存方法
    Store at -20℃ for one year(Powder);Store at 2-4℃ for two weeks;Store at -20℃ for six months after dissolution.
    基本信息
    别名
    ICG001;ICG 001
    外观
    Off-white powder
    可溶性/溶解性
    DMSO :100 mg/mL (182.27 mM)
    Ethanol :10 mg/mL (18.22 mM)
    生物活性
    靶点
    Wnt/β-catenin
    In vitro(体外研究)
    PRI-724 binds specifically to CBP but not the related transcriptional coactivator p300, thereby disrupting the interaction of CBP with β-catenin. Treatment with PRI-724 selectively induces apoptosis in colon carcinoma cells but not in normal colonic epithelial cells and reduces in vitro growth of colon carcinoma cells.
    In vivo(体内研究)
    PRI-724 exhibits antitumor activity in the mouse xenograft models of colon cancer. The initial results of the Phase I clinic trial of PRI-724 has been disclosed publically. The drug exhibits an acceptable toxicity profile with only one dose-limiting toxicity of grade 3 reversible hyperbilirubinaemia. An Open-Label dose-escalation phase I/II study of PRI-724 for patients with advanced myeloid malignancies is still ongoing.
    温馨提示:本产品仅作科研实验使用,不支持临床等研究
    • 实验方法 实验条件
      0张,还能上传 8 提交
          提示: 尊敬的客户您好,如果您对我们的产品有什么疑问或想要了解的,可以点击“我要提问”按钮填写您的疑问。
          提交不成功?请联系info@absin.cn。
          我要提问

      促销资讯 更多

        订购信息
        您可以从我们的授权经销商处购买absin产品或获得技术支持。若要查看您所在地区的经销商,请从以下的下拉列表中选择。
        GO
        • 0